Abbott Laboratories vs Stanley Black & Decker, Inc. — how do they compare? Abbott Laboratories trades at $111.12 (market cap $187.95B), while Stanley Black & Decker, Inc. trades at $103.22 (market cap $15.71B). The key difference: Abbott Laboratories is far larger — about 12× Stanley Black & Decker, Inc.'s market cap, and Stanley Black & Decker, Inc. pays the higher dividend (3.23%). Which is the better fit depends on your goals.
| ABT | SWK | |
|---|---|---|
Market Cap | $187.95B | $15.71B |
Sector | Health | — |
52-Week High | $136.62 | $104.00 |
52-Week Low | $82.57 | $62.12 |
Enterprise Value | $214.96B | $19.87B |
Dividend Yield | 2.32% | 3.23% |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
SWK trades at $102.9, up 0.25% today, with a bullish technical signal from moving averages but overbought RSI levels near 80. The company reported strong Q2 2026 earnings, beating EPS estimates with $1.57 versus $1.21 expected, and raised full-year guidance. Revenue for 2025 was $15.13B, with net income margin improving to 2.65%. Recent news highlights a $1 billion U.S. investment plan and institutional buying, supporting positive momentum.
The outlook is cautiously optimistic, with earnings growth and margin expansion driving potential upside, though the stock trades above the consensus price target of $93.67. Risks include debt levels and economic sensitivity, but institutional accumulation and dividend stability offer support. The current price near resistance at $105 may limit near-term gains despite fundamental improvements.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →